EUVIMEDEUVIMED entdecken
Crossref

Clinically Meaningful Response on the Rett Syndrome Behavior Questionnaire: A Responder Analysis of Patients Treated with Trofinetide Versus Placebo in the 12-Week LAVENDER Trial

Krithika Rajagopalan, Mirko Sikirica, Vinod Yakkala, Nazia Rashid, Sara Rhee, Walter E. Kaufmann

Journal of Child and Adolescent Psychopharmacology · 19.11.2026

DOI: 10.1177/10445463261508978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 19.11.2026. Verfasst von Krithika Rajagopalan und 5 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Gefördert von: ACADIA Pharmaceuticals.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Rett Syndrome Behavior Questionnaire (RSBQ), a caregiver-reported measure that assesses behavioral manifestations of Rett syndrome (RTT), is used as a primary endpoint in RTT clinical trials, including the pivotal trofinetide studies. However, a minimal clinically important difference (MCID) for the RSBQ mean total score has not been established, limiting patient-level interpretation of change.

Methods

MCID on the RSBQ was established using distribution- and anchor-based methods from data in RETT-002 (phase 2, 6-week, double-blind, randomized, placebo-controlled; N = 82) and LAVENDER (phase 3, 12-week, double-blind, randomized, placebo-controlled; N = 187) trofinetide trials. While distribution-based estimates were calculated as 0.4–0.5 × pooled standard deviation (SD) across treatment arms, anchor-based MCIDs were derived using between-patient and within-patient score changes on the Clinical Global Impressions-Improvement (CGI-I) scale by applying the upper bound of the 95% limits of agreement. The percentage of responders at week 12 was evaluated using MCID-based (who fit the responder criteria using both distribution and anchor-based methods) and threshold-based (≥15% improvement) mean total RSBQ score change from baseline. Adjusted multivariable logistic regressions assessed the association between treatment (trofinetide vs. placebo) and MCID-responder status. Sensitivity analysis examined patients who were both RSBQ responders and CGI-I responders (i.e., any improvement).

Results

Pooled SDs yielded MCID ranges of ∼4.6–5.9 points (baseline) and 3.2–4.4 points (change from baseline) using distribution methods while anchor-based estimates ranged from ∼3–9 points. Together, these findings supported an overall clinically meaningful improvement range of 3–9 points on the RSBQ. A ≥6-point improvement in mean total RSBQ score, representing the midpoint of the MCID range across distribution- and anchor-based methods, was selected as the conservative responder threshold. At week 12 in LAVENDER, trofinetide versus placebo had higher percentages of MCID-based (42.11% vs. 22.35%; p < 0.05) and threshold-based (39.47% vs. 18.82%; p < 0.05) responders, respectively. Trofinetide was associated with greater than two-fold higher odds of response versus placebo (adjusted OR: 2.54; 95% CI: 1.24–5.17; p < 0.05). Sensitivity analyses also favored trofinetide versus placebo (21.05% vs. 5.88%; p < 0.05).

Conclusions

Overall, a 3- to 9-point improvement on the mean total score, which may reflect meaningful changes in day-to-day symptoms such as mood, anxiety, and repetitive behaviors, was estimated to be the MCID range for RSBQ among individuals with RTT. In clinical trials, trofinetide versus placebo had a higher likelihood of achieving MCID- and threshold-based clinically meaningful improvements.

Förderung

  • ACADIA Pharmaceuticals

Zitieren

APA

Rajagopalan, K., Sikirica, M., Yakkala, V., Rashid, N., Rhee, S., & Kaufmann, W. E. (2026). Clinically Meaningful Response on the Rett Syndrome Behavior Questionnaire: A Responder Analysis of Patients Treated with Trofinetide Versus Placebo in the 12-Week LAVENDER Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1177/10445463261508978

Vancouver

Rajagopalan K, Sikirica M, Yakkala V, Rashid N, Rhee S, Kaufmann WE. Clinically Meaningful Response on the Rett Syndrome Behavior Questionnaire: A Responder Analysis of Patients Treated with Trofinetide Versus Placebo in the 12-Week LAVENDER Trial. Journal of Child and Adolescent Psychopharmacology. 2026. doi:10.1177/10445463261508978

BibTeX
@article{Rajagopalan2026,
  author = {Rajagopalan, Krithika and Sikirica, Mirko and Yakkala, Vinod and Rashid, Nazia and Rhee, Sara and Kaufmann, Walter E.},
  title = {Clinically Meaningful Response on the Rett Syndrome Behavior Questionnaire: A Responder Analysis of Patients Treated with Trofinetide Versus Placebo in the 12-Week LAVENDER Trial},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  doi = {10.1177/10445463261508978}
}
Kostenlos starten →